4,623 Shares in Johnson & Johnson $JNJ Acquired by Blalock Williams LLC

Blalock Williams LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,623 shares of the company’s stock, valued at approximately $857,000.

Several other hedge funds have also recently made changes to their positions in the company. SOA Wealth Advisors LLC. increased its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after acquiring an additional 53 shares during the last quarter. Ethos Financial Group LLC boosted its position in Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after purchasing an additional 53 shares during the period. Heritage Oak Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 3.5% in the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $304,000 after purchasing an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. raised its position in shares of Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares during the period. Finally, Wynn Capital LLC lifted its stake in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after buying an additional 57 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $218.81 on Friday. The firm has a 50 day simple moving average of $205.82 and a two-hundred day simple moving average of $186.95. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. Johnson & Johnson has a one year low of $141.50 and a one year high of $220.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. Morgan Stanley raised their target price on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Guggenheim upped their price target on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.